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Abstract
Background This study was designed to assess 
the long-term safety and tolerability of a new 
ﬂ  exible extended regimen of ethinylestradiol (EE) 
20 μg/drospirenone (DRSP) 3 mg, which allows 
management of intracyclic (breakthrough) bleeding 
[ﬂ  exible management of intracyclic (breakthrough) 
bleeding (MIB)], in comparison to conventional 
28-day and ﬁ  xed extended regimens.
Study design In this Phase III, multicentre, 
open-label study, women (aged 18–35 years) 
were randomised to EE/DRSP in the following 
regimens: ﬂ  exibleMIB (24–120 days’ active hormonal 
intake followed by a 4-day tablet-free interval), 
conventional 28-day (24 days’ active hormonal 
intake followed by a 4-day hormone-free interval) 
or ﬁ  xed extended (120 days’ uninterrupted active 
hormonal intake followed by a 4-day tablet-free 
interval) during a 1-year comparative phase. 
Thereafter, women entered a 1-year safety 
extension phase in which the majority received the 
ﬂ  exibleMIB regimen. Safety/tolerability outcomes 
were measured over 2 years. A separate analysis of 
certain safety parameters (endometrial, hormonal, 
lipid, haemostatic and metabolic variables) was 
conducted at two of the study centres.
Results Results were analysed in 1067 and 783 
women in the comparative and safety extension 
phases. Overall, 56.3% of women experienced ≥1 
adverse event (AE) in the safety extension phase. 
Serious AEs occurred in 3.0%, 1.4% and 3.3% 
of women receiving the ﬂ  exibleMIB, conventional 
and ﬁ  xed extended regimens, respectively. 
No unexpected endometrial, hormonal, lipid, 
haemostatic or metabolic ﬁ  ndings occurred with 
any of the three regimens.
Conclusions  EE/DRSP in a ﬂ  exible extended 
regimen with management of intracyclic 
(breakthrough) bleeding is well-tolerated and, 
when administered for up to 2 years, has 
a good safety proﬁ  le comparable to other 
estrogen/progestogen oral contraceptives.
Introduction
Most combined oral contraceptives 
(COCs) follow a 28-day intake cycle, 
consisting of 21 days of active hormonal 
intake followed by a 7-day hormone-
free interval. Some COCs are available 
in a 24/4-day regimen (24 days of active 
  hormonal intake followed by a 4-day 
  hormone-free interval); although 24/4-day 
regimen COCs have been shown to pro-
vide more sustained ovarian suppression 
and reduced   hormonal fluctuations com-
pared with 21/7-day regimens,1 they still 
follow the traditional 28-day cycle para-
digm. This cycle was adopted so that COC 
users would have a withdrawal bleed every 
4 weeks (i.e. have a menstrual cycle that 
mimicked the natural menstrual cycle).2
Recently, fixed extended regimen COCs 
have become available. With such regi-
mens, users do not experience a monthly 
withdrawal bleed because the active hor-
monal intake period is extended, result-
ing in fewer hormone-free intervals. Fixed 
extended regimen COCs may be appeal-
ing to the not insubstantial proportion 
of women who would welcome a reduc-
tion in the frequency of their menstrual 
bleeding.3 4 Unfortunately, fixed extended 
regimen COCs are not currently available 
outside of the USA.
Given the interest that women have in 
reducing and also being able to control 
when they have their menstrual bleed-
ing, it was considered that a regimen of 
ethinylestradiol (EE) 20 µg/drospirenone 
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Key message points
▶   A ﬂ  exible extended regimen of ethinylestradiol (EE) 
20 μg/drospirenone (DRSP) 3 mg, which allows 
women to extend their menstrual cycle and manage 
intracyclic (breakthrough) bleeding, is well-tolerated.
▶   When administered for up to 2 years, a ﬂ   exible 
extended regimen of EE/DRSP has a good safety 
proﬁ  le comparable to other estrogen/progestogen 
combined oral contraceptives.
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(DRSP) 3 mg that extended beyond the conventional 
28 days and that enabled the management of intra-
cyclic (breakthrough) bleeding (MIB), which can occur 
with fixed extended regimen COCs, would be appeal-
ing. The objective of this 2-year study was to compare 
the safety and tolerability of EE/DRSP in a flexible 
extended regimen with MIB (‘flexibleMIB’) with EE/
DRSP in a conventional 28-day or a fixed extended 
regimen. The efficacy, bleeding data and 1-year safety 
of the three regimens has been reported elsewhere.5 
This paper focuses on the safety and tolerability over 
2 years. In addition, a separate analysis was conducted 
to assess bone mineral density (BMD) and bone mark-
ers in women receiving the fixed extended regimen 
relative to the conventional regimen. This was because 
it has been reported that bone loss can occur during 
the use of depot contraceptives containing medroxy-
progesterone acetate,6 which has been speculated to be 
the result of prolonged ovarian suppression leading to 
reduced ovarian estradiol production.7
Methods
Study design
This was a Phase III, multicentre, randomised, open-
  label, parallel-group study conducted between December 
2005 (first subject, first visit) and October 2008 (last 
subject, last visit) at 37 centres in Canada, Germany 
and The Netherlands (protocol number, 308683; 
ClinicalTrials.gov identifier, NCT00266032).
The study was conducted in two phases. In the 
comparative phase, women were randomly allocated 
to receive one of three different regimens of EE/
DRSP for 1 year: a flexibleMIB regimen, a conventional 
28-day regimen or a fixed extended regimen. In order 
to provide long-term safety data for the flexibleMIB 
regimen, all subjects who completed the compara-
tive phase of the study were eligible to participate in 
a 1-year safety extension phase. During the safety 
extension phase, the majority of women received 
the flexibleMIB   regimen. There was, however, a small 
number of women (n=28) on the fixed extended and 
conventional   regimens who remained on their respec-
tive first-year regimens in order to assess BMD and 
bone markers.
The study was conducted in accordance with 
the Declaration of Helsinki and the International 
Conference on Harmonisation–Good Clinical Practice 
guidelines. Participants could enter the study only if 
they had received adequate information about it, and 
had voluntarily signed an informed consent form.
Study population
The study population plus the inclusion and exclusion 
criteria have been described in detail elsewhere.5 In 
Figure 1  Overview of subgroup analyses undertaken during the 1-year comparative treatment phase and the 1-year safety 
extension phase. MIB, management of intracyclic (breakthrough) bleeding.
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brief, healthy females aged between 18 and 35 years 
who requested contraceptive protection were eligible 
for inclusion. Smokers over the age of 30 years were 
ineligible to participate.
Study treatments
During the comparative phase, women received one of 
three different regimens of EE 20 µg/DRSP 3 mg. With 
the flexibleMIB regimen, women received EE/DRSP for 
a flexible number of cycles. Tablets were taken for at 
least 24 days (‘mandatory phase’); in this manner, the 
minimum cycle length was 28 days and the design of 
the COC was based on the approved and marketed 
conventional 24/4-day regimen of EE 20 µg/DRSP 
3 mg (YAZ®; Bayer HealthCare Pharmaceuticals). After 
the mandatory phase, the cycle could continue up to a 
maximum of 120 consecutive days (i.e. for a maximum 
cycle length of 124 days). During Days 25–120 (‘flex-
ible phase’), women were instructed to have a 4-day 
tablet-free interval if bleeding and/or spotting occurred 
for three consecutive days. The 4-day tablet-  free inter-
val was to be taken after no more than 120 days of 
continuous tablet intake. After a 4-day tablet-free 
interval, a new cycle with a minimum of 24 days and a 
maximum of 120 days of tablet intake was initiated.
For the conventional 28-day regimen, women 
received EE/DRSP for 13 cycles. Each cycle comprised 
24 days of active hormonal intake followed by 4 days 
of placebo tablets (hormone-free interval) to induce 
withdrawal bleeding.
For the fixed extended regimen, women received EE/
DRSP for three cycles. Each cycle comprised 120 days 
of uninterrupted active hormonal intake, regardless of 
any bleeding/spotting, followed by a 4-day tablet-free 
interval to induce withdrawal bleeding.
All women who completed the comparative phase 
of the study were eligible to participate in the safety 
extension phase. Women who received the flexibleMIB 
regimen in the comparative phase continued to do so 
in the safety extension phase. All women on the other 
two regimens, except those participating in the analysis 
investigating BMD and bone markers, were allowed to 
switch to the flexibleMIB regimen for the safety exten-
sion phase.
Full details regarding how study medication was dis-
pensed, when it was started and guidelines regarding 
study drug intake are reported elsewhere.5
Study variables
The primary and secondary efficacy variables are 
defined and reported elsewhere.5 Safety was evaluated 
by assessing adverse events (AEs), general physical and 
gynaecological findings (including the outcomes of cer-
vical smear tests), laboratory variables, vital signs and 
body weight. A separate safety analysis of the effects 
of treatment on endometrial characteristics (histology 
and thickness), ovarian morphology, metabolic param-
eters and hormone levels was conducted and assessed 
at two of the study centres (one in Germany and one 
in The Netherlands) (Figure 1). The effect of treatment 
Figure 2  Disposition of women through the 1-year comparative phase and the 1-year safety extension phase. MIB, management 
of intracyclic (breakthrough) bleeding. *Additional information on the disposition of women through the comparative phase of the 
study is published separately.5 **All women who entered the safety extension phase received ethinylestradiol 20 μg/drospirenone 
3 mg in the ﬂ  exibleMIB regimen with the exception of 28 women participating in the bone mineral density analysis. Such women 
continued to receive either the conventional or the ﬁ  xed extended, as shown in the ﬁ  gure.
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on BMD and bone markers was also assessed in a small 
number of women participating in the study (Figure 1).
Endometrial biopsies were performed using a small 
curette, and endometrial material was obtained from 
the anterior and/or posterior wall in the area of the 
fundus. Biopsies were postponed if subjects had men-
strual bleeding or spotting, had not taken tablets for at 
least 10 days or had an acute clinically relevant genital 
infection. Biopsies were analysed by a single reader. 
Endometrial thickness and ovarian morphology were 
assessed by transvaginal ultrasound.
Metabolic parameters were analysed using blood 
samples collected from women who had fasted for 
12 hours. A total of 25 ml of blood was needed from 
each subject for all of the metabolic parameters, 
with the exception of the oral glucose tolerance test 
(OGTT), which was undertaken to assess carbohydrate 
metabolism. For the OGTT, subjects were instructed to 
consume a balanced diet (no alcohol and no excessive 
consumption of any food) on the day preceding each 
of the tests. The tests were performed after a 12-hour 
overnight fast. The 75 g standardised OGTT involved 
taking five blood samples (3 ml each) 30 minutes 
before and at 30, 60, 90 and 120 minutes after inges-
tion of a glucose load. Hormone levels were measured 
from blood samples. A total of 7.5 ml of blood was 
needed for each sample per subject.
For those women included in the analyses of 
endometrial characteristics, metabolic parameters and 
hormone levels who had received sex hormone prior 
to the study, a washout period of 2 months (i.e. two 
menstrual cycles) was required before study medica-
tion could be initiated.
BMD of the lumbar spine (L1 to L4) and hip 
(femoral neck and total hip) was assessed by dual 
energy X-ray absorptiometry. At each visit, two BMD 
measurements were taken at each anatomical site. 
Measurements of bone markers in serum [estradiol, 
plasma osteocalcin, bone-specific alkaline phosphatase 
and carboxy-  terminal cross-linking telopeptide (CTx)] 
were assessed using blood samples taken in the morn-
ing after a 10-hour fast. Women were only eligible to 
participate in the analysis of BMD and bone markers 
if the mean of two pretreatment BMD T-scores was 
greater than –1 at the lumbar spine site.
Statistical analysis
Descriptive statistics were calculated for quantitative 
data, while frequencies were given for categorical data.
The randomisation scheme for the flexibleMIB, fixed 
extended and conventional regimens in the two study 
centres in which the additional safety analyses were 
conducted was 1:1:1, which used a separate randomi-
sation list and schedule. Randomisation was conducted 
using blocks of three until the respective sample size 
defined for each specific investigation (Figure 1) was 
achieved. In those women recruited at all other cen-
tres, the randomisation ratio to the flexibleMIB, con-
ventional and fixed extended regimens was 4:1:1. To 
prevent selection bias an interactive voice response 
system was used for randomisation. Further details 
regarding the randomisation of women to the differ-
ent regimens are reported elsewhere.5
Analysis set
The full analysis set (FAS) was defined as all women 
who took at least one dose of study medication and for 
whom at least one clinical observation was available. 
Within the blind data review, 67 subjects from one 
study centre had to be excluded from the FAS because 
of suspected misconduct. The evaluation of safety data 
was based on the FAS.
Table 1  Occurrence of adverse events (AEs) during the 1-year safety extension phase (full 
analysis set). (AEs are shown for all women who participated in the safety extension phase 
and according to the regimens received in the 1-year comparative phase)
Adverse event [n (%)] 
Regimen received in comparative phase†
All women 
(n=727)
FlexibleMIB 
(n=453)
Conventional 
28-day (n=155)
Fixed extended 
(n=119)
Any AE 409 (56.3) 244 (53.9) 104  (67.1) 61 (51.3)
Most frequent AEs*
 Diarrhoea  39 (5.4)  25  (5.5)   7  (4.5)  7 (5.9)
 Headache  53 (7.3)  25  (5.5)  20 (12.9)  8 (6.7)
 Nasopharyngitis  81  (11.1)  51 (11.3)  19 (12.3) 11 (9.2)
Discontinued  due  to  AE   9 (1.1)   5  (1.0)   4  (2.4)  0  (0)
Any  SAEs  29 (2.7)  19  (3.0)   3  (1.4)  7 (3.3)
Data shown as mean (SD).
*AEs (shown in alphabetical order) are those that occurred in >5% of all women who participated in the 1-year safety 
extension phase.
†During the safety extension phase, all women received ethinylestradiol 20 μg/drospirenone 3 mg in the ﬂ  exibleMIB regimen 
with the exception of 28 women participating in the bone mineral density analysis. Such women continued to receive either 
the conventional 28-day or ﬁ  xed extended regimens.
AE, adverse event; MIB, management of intracyclic (breakthrough) bleeding; SAE, serious adverse event.
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Sample size
For safety reasons, a treatment duration equivalent to 
10 000 cycles of 28 days was to be achieved for the 
flexibleMIB regimen. It was assumed that after the first 
year comparative phase, 50% of all subjects would vol-
untarily agree to receive the flexibleMIB regimen in the 
safety extension phase. Assuming an annual dropout 
rate of 40%, approximately 660 subjects were needed 
for the flexibleMIB regimen, and 225 subjects were 
needed for each of the other two regimens.
The sample size for BMD measurements was based 
on the assumption that the 95% confidence inter-
val (CI) for the difference of mean BMD loss would 
exclude the value –2.3% [with an assumed standard 
deviation (SD) of 2.6%]. To achieve a power of at least 
90%, 28 ‘completers’ were needed per treatment arm. 
Assuming a dropout rate of 40%, 47 subjects were 
needed per treatment arm.
Results
Overall, 1312 women were screened for inclusion into 
the study and 1166 of these were randomly allocated 
to one of the three regimens. In total, 1067 women 
fulfilled the criteria for the FAS (flexibleMIB, n=642; 
conventional 28-day, n=216; fixed extended, n=209). 
The disposition of women through the comparative 
phase and the baseline demographic characteristics 
of the FAS are described elsewhere.5 A total of 783 
women proceeded to the safety extension phase; of 
these, 755 remained on or switched to the flexibleMIB 
regimen. The remaining women, who were participat-
ing in the analysis assessing BMD and bone markers, 
remained on the conventional regimen (n=21) or the 
fixed extended regimen (n=7) (Figure 2). The FAS in 
the safety extension phase was 727 (originally received 
the flexibleMIB regimen, n=453; originally received the 
conventional regimen, n=155; originally received the 
fixed extended regimen, n=119).
Adverse events
Details pertaining to tolerability and safety outcomes 
during the comparative phase of the study are reported 
separately.5
In the safety extension phase, at least one AE was 
experienced by 409 (56.3%) of all the women who par-
ticipated. The occurrence of AEs and serious adverse 
events (SAEs) (including all non-drug-related events), 
the most frequent AEs and discontinuations due to 
AEs, overall and according to the regimen received in 
the comparative phase, are shown in Table 1.
Overall, 9.8% of subjects who participated in the 
safety extension phase had an AE that was deemed 
to be possibly, probably or definitely related to study 
medication. There were no deaths reported in the 
study. Four women who received the flexibleMIB regi-
men had SAEs that were considered to be possibly 
related to study medication [focal nodular hyperplasia 
(n=1; diagnosed in the safety extension phase), uterine 
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leiomyoma (n=1; diagnosed in the comparative phase) 
and deep vein thrombosis (DVT) (n=2; diagnosed in 
the comparative phase)].
SAEs of special interest occurred in four patients who 
received the flexibleMIB regimen: three cases of DVT, 
including one case of a postoperative thrombosis, and 
one case of focal nodular hyperplasia of the liver. One 
case of DVT occurred in the left calf of a 22-year-old 
Caucasian non-smoker. The subject had received study 
medication for approximately 7 months, and before 
that had received other COCs for approximately 14 
months. The subject had no personal or family his-
tory of thrombosis and an assessment of clotting 
status showed normal values; however, diagnostic 
examination revealed a heterozygous prothrombin 
gene mutation (factor II) and a heterozygous factor V 
Leiden mutation. The woman was treated accordingly 
without the need for hospitalisation, and recovered 
approximately 4 months after diagnosis. The event 
was considered to be possibly related to the study med-
ication. The second case of DVT (of the right lower 
leg) occurred in a 25-year-old Caucasian non-smoker 
approximately 1 month after study medication was 
initiated. The subject had used a COC for 8 months 
before enrolling in the study. An assessment of clotting 
status showed normal values, and laboratory results 
excluded factor V and prothrombin gene mutations; 
however, the woman was found to have a family his-
tory of thrombosis and varices. The woman received 
treatment for 5 months. The event was considered to 
be possibly related to the study medication. The case of 
postoperative thrombosis (of the crural vein) occurred 
in a 29-year-old Caucasian non-smoker 1 day after 
knee surgery that took place approximately 2 months 
after starting study medication. The subject had used a 
COC for almost 1 year before starting the study. The 
event was considered to be most likely related to the 
knee surgery and postoperative immobilisation and 
unlikely to be related to the study medication.
The case of focal nodular hyperplasia of the liver 
occurred in a 20-year-old Caucasian smoker (10 ciga-
rettes daily) who had a 26-month history of COC use 
prior to study entry. Study medication was received for 
almost 19 months before being discontinued because 
of high alkaline phosphatase levels; prior to medica-
tion being discontinued, increasing values of alkaline 
phosphatase and γ-GT were found. Three months 
afterwards the subject was diagnosed with benign 
focal nodular hyperplasia in the right lobe of the liver. 
Neither the focal nodular hyperplasia nor the increased 
liver enzymes were treated with specific drugs or pro-
cedures. The relationship of the event to the study 
medication was defined as possible.
Safety laboratory evaluations
In general, changes in safety laboratory values were min-
imal with all three regimens over time. Only a small pro-
portion of subjects had high or low levels of laboratory 
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values. During the course of the study, there was a tran-
sient increase in the proportion of subjects with labora-
tory values for potassium that were above normal (peak 
proportion of 2.0% at Week 27 of the safety extension 
phase). That said, absolute changes from baseline were 
minimal, levels remained stable in all treatment groups 
and the proportion of subjects with levels above the nor-
mal range was similar to baseline at the end of the treat-
ment (Week 51 of the safety extension phase).
Endometrial and ovarian characteristics
The endometrium was characterised at the end of the 
comparative phase in 23 women who received the 
flexibleMIB regimen and in 17 women who received the 
fixed extended regimen. Most women who received 
the flexibleMIB and fixed extended regimens had an 
inactive endometrium (7/23 and 3/17 women), an 
atrophic endometrium (6/23 and 5/17 women) or a 
secretory endometrium of the progestational type (5/23 
and 4/17 women), respectively. A weakly proliferative 
endometrium occurred in 4/23 and 3/17 women. The 
endometrium was characterised at the end of the safety 
extension phase in seven women who had originally 
received the flexibleMIB regimen and in nine women who 
had originally received the fixed extended regimen. Most 
of these women had insufficient material for diagnosis; 
in those that did, an atrophic endometrium (4/7 women 
who originally received the flexibleMIB regimen and 0/9 
women who originally received the fixed extended regi-
men) or secretory endometrium of the progestational 
type (1/7 and 4/9 women, respectively) was the most 
common. No abnormal findings were identified, includ-
ing no hyperplasia, carcinomas, sarcomas, carcinomatous 
or other types of metaplasia or cervical carcinomas.
Endometrial thickness was assessed at Weeks 27 and 
51 of the comparative phase in 32 and 34 women who 
received the flexibleMIB regimen, 27 and 25 women 
who received the conventional regimen, and 28 and 
30 women who received the fixed extended regimen. 
At Week 27, mean endometrial thickness was 3.99 mm 
with the flexibleMIB regimen (vs 7.61 mm at baseline), 
3.99 mm with the conventional regimen (vs 7.08 mm 
at baseline) and 3.97 mm with the fixed extended 
regimen (vs 7.71 mm at baseline). Mean thickness at 
Week 51 was 4.27 mm, 3.94 mm and 4.48 mm, respec-
tively. Endometrial thickness was assessed at Week 51 
of the safety extension phase in nine women who had 
originally received the flexibleMIB regimen, 13 women 
who had originally received the conventional regimen 
and 10 women who had originally received the fixed 
extended regimen. Mean endometrial thickness was 
3.69 mm, 3.37 mm and 4.10 mm, respectively.
Ovarian morphology was assessed at Weeks 27 and 
51 in the comparative phase in 32 and 34 women who 
received the flexibleMIB regimen, 27 and 26 women 
who received the conventional regimen, and 28 and 30 
women who received the fixed extended regimen. One 
woman who received the conventional regimen was 
pregnant at Week 51 of the comparative phase. One 
woman who received the fixed extended regimen had 
suspected chocolate cysts on both ovaries at Week 27; 
this was confirmed by Week 51 following laparoscopic 
enucleation of the cysts. The woman prematurely dis-
continued study medication. Ovarian morphology was 
assessed at Week 51 of the safety extension phase in 
nine women who had originally received the flexibleMIB 
regimen, 13 women who had originally received the 
conventional regimen and 10 women who had origi-
nally received the fixed extended regimen. There were 
no abnormal findings in the safety extension phase.
Metabolic parameters
Changes in the serum lipid profile over time are shown 
in Table 2. Total cholesterol increased from baseline 
to a similar extent with all three regimens; a similar 
pattern was observed for triglycerides. Low-density 
lipoprotein cholesterol remained relatively unchanged 
in all three regimens, while high-density lipoprotein 
(HDL) cholesterol increased slightly to a similar extent 
in all three regimens.
Haemostatic parameters
Haemostatic variables were assessed at Weeks 27 and 
51 of the comparative phase in 22 and 20 women who 
received the flexibleMIB regimen, 22 and 22 women 
who received the conventional regimen and 25 and 
16 women who received the fixed extended regimen. 
A 2-month washout period from any treatment with 
sex hormones prior to the intake of study medication 
was a participation criterion. Increases in prothrombin 
fragment 1+2, D-dimer, fibrinogen, factor VII activ-
ity and protein C activity, relative to baseline levels, 
were observed at Weeks 27 and 51. Activated protein 
C resistance and protein S activity were decreased 
versus baseline at Weeks 27 and 51. Factor VIII activ-
ity was increased versus baseline at Week 27, but was 
decreased versus baseline at Week 51. In contrast, anti-
thrombin III was decreased versus baseline at Week 27, 
but was increased versus baseline at Week 51. Similar 
trends were observed in all three treatment groups with 
no between-treatment differences observed in changes 
in haemostatic variables.
Carbohydrate metabolism
An OGTT was performed at Weeks 27 and 51 of the 
comparative phase in 22 and 19 women who received 
the flexibleMIB regimen, 22 and 22 women who received 
the conventional regimen and 24 and 16 women who 
received the fixed extended regimen. Results of the 
OGTT showed that there was no evidence of impaired 
glucose tolerance during treatment with any of the three 
regimens. C-peptide measurements reflected changes in 
glucose levels during the OGTT and the insulin response 
following the OGTT, both of which were normal.
Hormone levels
Hormone levels were assessed in 20–26 women who 
received the flexibleMIB regimen, 22–24 women who 
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received the conventional regimen and 17–28 women 
who received the fixed extended regimen during 
treatment. Study participation required a minimum 
of 2 months without the use of sex steroids prior to 
intake of medication. There were decreases from base-
line in all three treatment groups in the levels of estra-
diol, follicle-stimulating hormone (FSH), luteinising 
hormone (LH) and testosterone. Changes in the levels 
of these hormones were rapid and were similar with all 
three regimens. Marked increases from baseline in the 
levels of sex hormone-binding globulin (SHBG) were 
observed with all three regimens; SHBG levels had 
increased by a factor of 3–4 at Week 3 of treatment, 
and by a factor of 4–5 at Week 51 of treatment.
Vital signs, serum chemistry and body weight
Mean heart rate, systolic blood pressure and diastolic 
blood pressure were stable throughout the course of 
the study in all three regimens. None of the regimens 
adversely affected blood pressure, and mean blood 
pressure recordings generally remained within nor-
mal limits. Overall changes in safety laboratory values 
(haematology, serum chemistry) were small in all three 
regimens, and the proportion of subjects with high or 
low levels of laboratory values was small. From base-
line to the end of the comparative phase, body weight 
remained stable in all three regimens. In the safety 
extension phase, there was a mean weight gain of 
approximately 1 kg; this was observed in all women, 
regardless of their regimen in the comparative phase.
Gynaecological examination
An abnormal cervical smear test at the end of the com-
parative phase was found in 13 (2.1%), 4 (1.9%) and 
5 (2.5%) women who received the flexibleMIB, conven-
tional and fixed extended regimens, respectively. At the 
end of the safety extension phase, an abnormal smear 
was observed in 13 (2.9%), 3 (2.0%) and 2 (1.8%) 
women who originally received the flexibleMIB, con-
ventional and fixed extended regimens, respectively. 
The most frequently reported abnormal findings from 
cervical smears were atypical squamous cells of unde-
termined significance and Papanicolaou (Pap) IIID. In 
one woman, Stage 0 cervical carcinoma was diagnosed 
less than 1 month after study medication (conven-
tional 28-day regimen) was initiated. The diagnosis 
was deemed unrelated to study medication.
Bone mineral density and bone markers
At the end of both phases of the study, there were no 
appreciable changes in lumbar spine or hip BMD in 
the small number of women who received the fixed 
extended or conventional regimens for 2 years (Table 3). 
Similar decreases in the levels of osteocalcin, bone 
alkaline phosphatase and CTx were observed with the 
fixed extended and conventional regimens.
Discussion
This two-phase study indicates that EE/DRSP adminis-
tered in a flexibleMIB regimen is well-tolerated and has 
an acceptable safety profile when administered for a 
period of up to 2 years. A low number of treatment-
related SAEs were reported and no deaths occurred 
during the study. The flexibleMIB regimen has also been 
shown to have reliable contraceptive efficacy.5
Only four SAEs were considered to be possibly related 
to study medication: focal nodular hyperplasia, uterine 
leiomyoma and two cases of DVT. DVT and pulmonary 
embolism, collectively referred to as venous throm-
boembolism (VTE), are rare events in users of hormonal 
contraceptives. Nonetheless, the use of estrogen-pro-
gestogen combination products, including COCs, is a 
known risk factor for VTE, with the risk being highest 
during the initial months of use.8 9 Additional risk fac-
tors include increasing age, increasing body mass index, 
genetic mutations that affect coagulation, and a family 
history of VTE.9 10 One DVT case that was deemed to 
be possibly related to study medication occurred in a 
woman 1 month after the study medication was initi-
ated. Contrary to initial information, the woman had a 
family history of thrombosis, which was an exclusion cri-
terion of the study. The other case occurred in a woman 
approximately 7 months after treatment was initiated; 
diagnostic examination revealed that this woman had a 
heterozygous prothrombin gene mutation (factor II) and 
a heterozygous factor V Leiden mutation. A third VTE 
was considered to be most likely related to knee surgery 
and the postoperative immobilisation. It is not possible 
to evaluate the risk of rare events such as VTE using the 
results of clinical trials such as this one that have limited 
treatment exposure. That said, this topic needs to be 
investigated in robust postmarketing epidemiological 
studies. The risk of thrombotic events has been associ-
ated with estrogen, although controversy remains as to 
whether or not there may be an increased risk of VTE 
associated with specific progestogens. Recent database 
studies have suggested that the risk of VTE is lower in 
women using levonorgestrel-containing COCs relative 
to women using so-called ‘third-generation’ COCs, and 
women using COCs containing DRSP .11–14 These find-
ings are in contrast to those of the European Active 
Surveillance Study (EURAS)9 and the Ingenix database 
study,15 which show that the risk of VTE is compara-
ble for low-dose COCs, regardless of the type of pro-
gestogen included.
The use of COCs is associated with distinct changes 
in endometrial histology, including the inhibition of 
glandular growth and differentiation, often resulting in 
an inactive or atrophic endometrium.16 These changes 
contribute to the contraceptive efficacy of COCs. In 
this study, endometrial biopsies showed that the use of 
the flexibleMIB or fixed extended regimens resulted in 
an inactive, atrophic or secretory endometrium in most 
women. These findings are similar to those reported for 
low-dose COCs administered in a 28-day regimen16–18 or 
as fixed extended regimens.19 20 Endometrial hyperpla-
sia or malignancy was not observed in any endometrial 
biopsy sample in the current study, comparable to other 
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safety profile that is comparable to other estrogen/ 
progestogen COCs.
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mens, levels of estradiol, FSH, LH and testosterone 
decreased compared with baseline; these changes were 
similar with all three regimens and were typical of 
those that occur during COC use.22–24 An increase in 
the levels of SHBG was observed, which is typical in 
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The results of the BMD analysis suggest that neither 
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a negative impact. This agrees with studies that have 
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no negative effects on BMD in young women.25 26 In 
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line phosphatase and CTx were observed with both 
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Conclusions
The results of this study show that EE/DRSP admin-
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